Biotechnology | COVID-19 | FDA
Quidel’s QuickVue At-Home OTC COVID-19 Test received EUA for screening use with serial testing
On Mar. 31, 2021, Quidel announced that it had received an Emergency Use Authorization (EUA) from the FDA,…
Pfizer-BioNTech announced positive topline results of pivotal COVID-19 vaccine study in adolescents
On Mar. 31, 2021, Pfizer and BioNTech announced that, in a Phase 3 trial in adolescents 12 to…
Celonic and CureVac announced agreement to manufacture over 100 million doses of CureVacﾒs COVID-19 vaccine CVnCoV
On Mar. 30, 2021, CureVac and Celonic Group announced their partnership for the production of CureVacﾒs mRNA-based COVID-19…
T cells recognize recent SARS-CoV-2 variants
On Mar. 30, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced that researchers had analyzed…
Measles vaccine used as base for experimental COVID vaccine
On Apr. 1, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that an investigational vaccine designed to…
WHO called for further studies, data on origin of SARS-CoV-2 virus
On Mar. 30, 2021, the report of the WHO international team on their Wuhan field visit, from 14…
BD announced FDA Emergency Use Authorization for combination COVID-19, flu rapid antigen test
On Mar. 30, 2021, BD (Becton, Dickinson) announced the U.S. Food and Drug Administration (FDA) granted emergency use…
OraSure Technologies submitted COVID-19 rapid antigen prescription home self-test to FDA for EUA
On Mar. 30, 2021, OraSure Technologies announced that it had submitted an application to the U.S. Food and…
Qx Therapeutics received FDA authorization with IND for QXT-101 in phase 2 trial for patients with COVID-19 infection.
On Mar. 30, 2021, Qx Therapeutics announced that the FDA had cleared the companyﾒs Investigational New Drug application…
CytoDyn’s leronlimab decreased mortality at 14 days by 82% amongst critically Ill COVID-19 patients
On Mar. 30, 2021, CytoDyn announced further results from its CD12 trial of severe-to-critically ill patients with COVID-19….
Oxford University researchers released cheap, quick COVID-19 antibody test
On Mar. 29, 2021, an international research team led by Oxford University scientists announced they had developed a…
Humanigen reported positive phase 3 results demonstrating Lenzilumabﾙ improved survival without mechanical ventilation with COVID-19
On Mar. 29, 2021, Humanigen announced positive topline results from its Phase 3 clinical trial evaluating the efficacy…
Moderna announced shipment of 100 millionth dose of its COVID-19 vaccine to the U.S. Government
On Mar. 29, 2021, Moderna announced that the Company has shipped the 100-millionth dose of its COVID-19 vaccine…
GSK to manufacture Novavax’ COVID-19 vaccine
On Mar. 29, 2021, Novavax, GSK and the UK Government Vaccines Taskforce announced an agreement in principle to…
Johnson & Johnson announced agreement with African Vaccine Acquisition Trust for COVID-19 vaccine candidate
On Mar. 29, 2021, Janssen Pharmaceutica announced that it had entered into an agreement with the African Vaccine…
Philippines FDA approved the use of leronlimab to treat a COVID-19 patient
On Mar. 29, 2021, CytoDyn announced that the Republic of the Philippines, Department of Health, Food and Drug…
FDA approved first cell-based gene therapy for adult patients with multiple myeloma
On Mar. 27, 2021, the FDA approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients…
FDA approved first in the world device to treat patients with congenital heart disease
On Mar. 26, 2021, the U.S. Food and Drug Administration (FDA) approved the first in the world non-surgical…
EMA approved new storage option for Pfizer-BioNTech vaccine, easing distribution and storage of doses
On Mar. 26, 2021, Pfizer and BioNTech announced that the European Medicines Agency (EMA) approved storage of COMIRNATYﾮ…
BioNTech updated on vaccine production status at Marburg manufacturing site
On Mar. 26, 2021, BioNTech announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19…
FDA approved Bristol Myers Squibbﾒs and bluebird bioﾒs Abecma for Relapsed or Refractory Multiple Myeloma
On Mar. 26, 2021, Bristol Myers Squibb and bluebird bio announced that the FDA had approved Abecma (idecabtagene…
Scientists found evidence that novel coronavirus infects the mouth’s cells
On Mar. 25, 2021, an international team of scientists announced they had found evidence that SARS-CoV-2 infects cells…
Biotechnology | HIV | Therapeutics | Vaccine
Oregon Health & Science University researchers unlocked HIV vaccine candidate’s mysteries 20 years later
On Mar. 25, 2021, about two decades after first devising a new kind of vaccine, Oregon Health &…
McGill University researchers led by Bratislav Misic announced a direct link between gene expression and higher brain function
On Mar. 25, 2021, McGill University researchers led by Bratislav Misic announced a direct link between gene expression…
Clover Biopharma and Dynavax announcd first participants dosed in phase 2/3 trial for COVID-19 vaccine candidate
On Mar. 24, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced the first participants have were dosed in Clover’s…
COVID-19 | Diagnostics | FDA
AXIM Biotechnologies’ partner Empowered filed EUA with FDA for use of rapid COVID-19 neutralizing antibody test
On Mar. 24, 2021, AXIM Biotechnologies announced that partner Empowered Diagnostics, had filed an Emergency Use Authorization or…
Thermo Fisher Scientific launched In-Air SARS-CoV-2 surveillance solution
On Mar. 24, 2021, Thermo Fisher Scientific announced the launch of the Thermo Scientific AerosolSense Sampler, a new…
Scientists found genetic link to clogged arteries
On Mar. 24, 2021, scientists from Washington University School of Medicine in St. Louis announced they had identified…
Virginia Tech and UVA virologists developed broadly protective coronavirus vaccines
On Mar. 24, 2021, Virginia Tech researchers announced that their candidate Coronavirus vaccines, prevented pigs from becoming ill…
CureVacﾒs COVID-19 vaccine candidate demonstrated protection against SARS-CoV-2 B1351 variant
On Mar. 23, 2021, CureVac announced publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protected…